Jack Anders Sells 4,053 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 4,053 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $807,519.72. Following the sale, the chief financial officer directly owned 119,216 shares of the company’s stock, valued at $23,752,595.84. This represents a 3.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jack Anders also recently made the following trade(s):

• On Wednesday, June 24th, Jack Anders sold 20,000 shares of Revolution Medicines stock. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00.

Revolution Medicines Trading Down 3.0%

Shares of NASDAQ:RVMD traded down $5.99 during trading on Friday, reaching $190.95. The stock had a trading volume of 5,937,950 shares, compared to its average volume of 2,930,039. The firm’s fifty day moving average is $199.49 and its 200 day moving average is $159.35. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. Revolution Medicines, Inc. has a 52 week low of $42.18 and a 52 week high of $224.31. The stock has a market cap of $40.93 billion, a price-to-earnings ratio of -21.65 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the business posted ($1.31) EPS. As a group, equities analysts forecast that Revolution Medicines, Inc. will post -8.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RVMD. Contravisory Investment Management Inc. purchased a new stake in Revolution Medicines during the second quarter valued at about $32,000. Johnson Financial Group Inc. bought a new stake in shares of Revolution Medicines in the second quarter valued at approximately $37,000. Silvant Capital Management LLC purchased a new stake in shares of Revolution Medicines during the 2nd quarter valued at approximately $41,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Revolution Medicines during the 2nd quarter valued at approximately $41,000. Finally, Allworth Financial LP boosted its holdings in Revolution Medicines by 57.2% in the 4th quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after buying an additional 210 shares during the period. 94.34% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Evercore reissued an “outperform” rating and issued a $320.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 27th. Wedbush raised their target price on Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Wolfe Research reaffirmed an “outperform” rating and issued a $220.00 price target on shares of Revolution Medicines in a research note on Monday, August 10th. Oppenheimer boosted their price objective on Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Finally, Royal Bank Of Canada upped their target price on shares of Revolution Medicines from $203.00 to $251.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $226.17.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.